{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:07:36Z","timestamp":1761959256002,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T00:00:00Z","timestamp":1614988800000},"content-version":"vor","delay-in-days":64,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine Case Reports"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.rmcr.2021.101385","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T21:09:07Z","timestamp":1615324147000},"page":"101385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Three cases of sequential treatment with nintedanib following pulsed-dose corticosteroids for acute exacerbation of interstitial lung diseases"],"prefix":"10.1016","volume":"33","author":[{"given":"Kazuki","family":"Nakashima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2212-0631","authenticated-orcid":false,"given":"Toyoshi","family":"Yanagihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sae","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naruhiko","family":"Ogo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayaka","family":"Egashira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuma","family":"Asoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashige","family":"Maeyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmcr.2021.101385_bib1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1183\/09031936.06.00114004","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features","volume":"27","author":"Kim","year":"2006","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmcr.2021.101385_bib2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis an international working group report","volume":"194","author":"Collard","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmcr.2021.101385_bib3","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.rmed.2008.12.019","article-title":"Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases","volume":"103","author":"Suda","year":"2009","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmcr.2021.101385_bib4","doi-asserted-by":"crossref","first-page":"180071","DOI":"10.1183\/16000617.0071-2018","article-title":"Acute exacerbations of progressive-fibrosing interstitial lung diseases","volume":"27","author":"Kolb","year":"2018","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.rmcr.2021.101385_bib5","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An Official ATS\/ERS\/JRS\/ALAT Statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmcr.2021.101385_bib6","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis: an update of the 2011 clinical practice guideline","volume":"192","author":"Raghu","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmcr.2021.101385_bib7","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmcr.2021.101385_bib8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.rmed.2016.02.001","article-title":"Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS\u00ae trials","volume":"113","author":"Richeldi","year":"2016","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmcr.2021.101385_bib9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S2213-2600(18)30339-4","article-title":"Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON","volume":"7","author":"Crestani","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmcr.2021.101385_bib10","first-page":"317","article-title":"Therapeutic effect of nintedanib on acute exacerbation of interstitial lung diseases","volume":"26","author":"Ito","year":"2019","journal-title":"Respir. Med. Case Reports."},{"key":"10.1016\/j.rmcr.2021.101385_bib11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/rcr2.215","article-title":"Treatment with nintedanib for acute exacerbation of idiopathic pulmonary fibrosis","volume":"5","author":"Tomioka","year":"2017","journal-title":"Respirol. Case Reports."},{"key":"10.1016\/j.rmcr.2021.101385_bib12","doi-asserted-by":"crossref","first-page":"105920","DOI":"10.1016\/j.rmed.2020.105920","article-title":"Clinical characteristics of patients with anti-EJ antisynthetase syndrome associated interstitial lung disease and literature review","volume":"165","author":"Liu","year":"2020","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmcr.2021.101385_bib13","first-page":"101272","article-title":"Nintedanib and intensive immunosuppressive therapy to treat rapidly progressive interstitial lung disease presenting anti-ARS antibodies","volume":"31","author":"Yanagihara","year":"2020","journal-title":"Respir. Med. Case Reports"},{"key":"10.1016\/j.rmcr.2021.101385_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmed.2021.626953","article-title":"Efficacy and tolerability of nintedanib in idiopathic-inflammatory-myopathy-related interstitial lung disease: a pilot study","volume":"8","author":"Liang","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.rmcr.2021.101385_bib15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.resinv.2020.08.003","article-title":"Tolerability and safety of nintedanib in elderly patients with idiopathic pulmonary fibrosis","volume":"59","author":"Uchida","year":"2021","journal-title":"Respir. Investig."},{"key":"10.1016\/j.rmcr.2021.101385_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-11321-x","article-title":"Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis","volume":"7","author":"Ikeda","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.rmcr.2021.101385_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-48593-4","article-title":"Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis","volume":"9","author":"Kato","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.rmcr.2021.101385_bib18","first-page":"74","article-title":"Association of low body surface area with dose reduction and\/or discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis: a pilot study","volume":"36","author":"Toi","year":"2019","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.rmcr.2021.101385_bib19","series-title":"Am. J. Respir. Crit. Care Med.","article-title":"Nintedanib treatment for elderly patients with idiopathic pulmonary fibrosis","author":"Ochi","year":"2019"},{"author":"Drug Information for Nintedanib","key":"10.1016\/j.rmcr.2021.101385_bib20"},{"key":"10.1016\/j.rmcr.2021.101385_bib21","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.resinv.2018.12.010","article-title":"Low starting-dosage of nintedanib for the reduction of early termination","volume":"57","author":"Ikeda","year":"2019","journal-title":"Respir. Investig."},{"issue":"1","key":"10.1016\/j.rmcr.2021.101385_bib24","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S2213-2600(18)30339-4","article-title":"Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON","volume":"7","author":"Crestani","year":"2019","journal-title":"The Lancet Respiratory Medicine"},{"key":"10.1016\/j.rmcr.2021.101385_bib23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.rmed.2017.03.026","article-title":"Pirfenidone for acute exacerbation of idiopathic pulmonary fibrosisA retrospective study","volume":"126","author":"Furuya","year":"2017","journal-title":"Respir. Med."}],"container-title":["Respiratory Medicine Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007121000472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007121000472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:03:24Z","timestamp":1761959004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213007121000472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":23,"alternative-id":["S2213007121000472"],"URL":"https:\/\/doi.org\/10.1016\/j.rmcr.2021.101385","relation":{},"ISSN":["2213-0071"],"issn-type":[{"type":"print","value":"2213-0071"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Three cases of sequential treatment with nintedanib following pulsed-dose corticosteroids for acute exacerbation of interstitial lung diseases","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmcr.2021.101385","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101385"}}